Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Melanoma 3Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors, Adult 1Skin Neoplasms 1Lung Neoplasms 1Lung Diseases 1Carcinoma 1Bronchial Neoplasms 1

Interventions

pembrolizumab 34Cisplatin 30Brachytherapy 16Paclitaxel 15Carboplatin 15Bevacizumab 15Radiotherapy 14Blood Specimen Collection 13Specimen Handling 12Magnetic Resonance Spectroscopy 11Colposcopy 11Nivolumab 10Drug Therapy 10atezolizumab 8Human Papillomavirus DNA Tests 8Gemcitabine 8lenvatinib 7Radiation 6Platinum 6Biopsy 6toripalimab 5cemiplimab 5Surveys and Questionnaires 5Standard of Care 5Radiotherapy, Intensity-Modulated 5Practice Guidelines as Topic 5Patient Navigation 5Methods 5Fulvestrant 5Fluorodeoxyglucose F18 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Toll-Like Receptor 1 × 1 year × Clear all
NCT03108495 2025-09-17

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

Iovance Biotherapeutics, Inc.

Phase 2 Terminated
210 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡